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Risk Stratification and Management Strategies
Introduction
Epidemiology
Dural arteriovenous malformations (DAVMs), also known as dural arteriovenous fistulas, are 
arteriovenous shunts from a dural arterial supply to a dural venous channel, typically supplied by 
pachymeningeal arteries and located near a major venous sinus.1 The etiology of these lesions is 
not fully understood. DAVMs in the pediatric population are associated with structural venous 
abnormalities ,2 but the majority of DAVMs are thought to be acquired. Different etiologies have 
been implicated in this phenomenon, namely: sinus thrombosis, trauma or surgery.2–6 
DAVMs have been reported in all age groups, but mainly in the fifth and sixth decades of life.7–9 
The estimated incidence of DAVMs is 0.17 per 100,00010, 11 and they are one fifth as common as 
arteriovenous malformations (AVMs).10, 12 They represent 10% to 15% of all intracranial vascular 
malformations,10, 12–17 with a higher incidence in women. In fact, a female/male ratio of 2/1 exists in 
certain anatomic sites such as the cavernous and transverse-sigmoid sinuses.6–8, 18–20 AVMs are usually 
solitary, nonetheless in 5% of cases multiple lesions have been described.10, 21, 22
Natural History
DAVMs are usually acquired.6, 23 Recent experimental work suggests that the wide array of clinical 
associations of DAVM may be explained by the development of venous obstruction and hypertension 
with aberrant angiogenesis.24 It is hypothesized that their development arises from altered angiogenesis 
within the dura following an inciting event such as trauma, surgery or chronic infection. Sinus thromboses 
can be an accompanying factor in these cases. Cases have been documented of angiographically proven 
dural sinus thrombosis in which DAVMs subsequently developed as a consequence of the obstructed 
sinus. Next, initial microshunts proliferate in association with venous hypertension, and mature into 
clinically significant arteriovenous fistulae. The degree of progression or involution determines the 
significance of the abnormality. These fistulas may result in hemorrhage or other focal manifestations 
including hemodynamic insufficiency. DAVMs cause decreased regional cerebral blood flow in cortical 
regions where there is retrograde venous drainage.25 
The development of DAVMs following trauma and surgery is well known.25, 26 They have also been 
reported in association with chronic infection, vascular disease and tumors.27 Other cases of DAVM 
have no clear association. They may be identified at anatomical sites distinct from the presumed 
inciting event. The exact mechanism of development remains unclear. It is well established that the 
development of a DAVM in these diverse settings requires a common mechanism as well as a possible 
anatomic or genetic predisposition.28, 29 
An established DAVM may follow one of several unpredictable natural courses. Some lesions remain 
asymptomatic or maintain stable clinical symptomatology and angiographic features over many years. 
Others undergo spontaneous regression, involution and resolution with stabilization or improvement 
of neurological symptoms.30–35 Features that may predispose to such spontaneous involution are not 
known. In fact, DAVMs in the region of the cavernous sinus are particularly prone to this phenom-
enon with as many as 40 percent of reported cases having undergone spontaneous involution. 
In contrast, some DAVMs may demonstrate 
increase in size from either arterial or venous 
enlargement 1, 12, 36 or even de novo develop-
ment.37 Pachymeningeal arterial feeders may 
be progressively recruited with enlargement 
of the nidus. The mechanisms behind this 
progressive recruitment of arterial feeders from 
numerous sources have not been elucidated. 
This phenomenon results in hypertrophy of 
dural arteries and the reappearance of involuted 
embryonic arteries that may not normally be 
visible in the adult dura mater. In some DAVMs 
there is also progression of pathology on the 
venous side. Progressive arterialization of the 
pathologic dural leaflets results in hypertension 
in adjacent leptomeningeal venous channels. 
This may lead to retrograde leptomeningeal 
venous drainage. Under arterialized pressures 
these channels may become tortuous and, 
eventually, varicose or aneurysmal. The cata-
strophic consequence that ensues is a cerebral 
hemorrhage from cortical venous drainage. In 
DAVMs that present with intracranial hem-
orrhage and have retrograde cortical venous 
drainage, there is a 35% risk of rebleeding 
within the first 2 weeks. 38
Presentation
Clinical manifestations of DAVMs are highly 
variable and are related primarily to the 
location of the fistula as well as from the ret-
rograde cortical venous drainage as described 
above. These range from minor symptoms to 
intracranial hemorrhage. The vast majority 
of symptoms can be attributed to the primary 
or secondary venous manifestations of the 
DAVM. Presentation may be sudden or slowly 
progressive. The degree and type of symp-
toms are determined by venous topography, 
venous flow pattern and the capacity of sur-
rounding compensatory venous drainage. As 
above, the most serious neurological sequelae 
from DAVMs are associated with retrograde 
leptomeningeal venous drainage. 12 Focal 
neurological deficits likely result from venous 
hypertension and intracranial hemorrhage from 
rupture of arterialized leptomeningeal veins. 
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There are a wide variety of non-hemorrhagic 
symptoms. 39, 40 More benign symptoms of pain, 
tinnitus or bruit are related to arteriovenous 
shunting and flow in the DAVM. Pulsatile 
tinnitus or other subjective auditory symptoms 
may occur with or without pain. These symp-
toms are likely related to high flow through 
dural vascular channels at the base of the skull. 
Other painful complaints may be related to 
orbital congestion or stretching of dural leaflets 
by engorged vascular channels, or to direct 
compression of the trigeminal nerve by arteri-
alized venous structures near the petrous apex. 
A variety of neuro-ophthalmologic manifesta-
tions of DAVMs include visual and gaze abnor-
malities caused by venous hypertension, as well 
as orbital or ocular venous hypertension with 
resulting orbital crowding, venous stasis reti-
nopathy and glaucoma. Other cranial DAVMs 
may present with symptoms of increased intra-
cranial pressure (ICP) or a poorly defined head-
ache. 41, 42 While the headaches are non-specific, 
there does appear to be an association with the 
dysplastic changes in meningeal vessels which 
are often present in DAVMs . There are also a 
wide spectrum of presenting focal neurological 
symptoms including seizure, hearing loss, cra-
nial nerve palsy, papilledema and other visual 
symptoms and focal motor/sensory deficits. 43–47 
DAVMs may also result in altered cerebro- 
spinal (CSF) hydrodynamics.48 Dilated venous 
structures may act as mass lesions, obstructing 
the CSF circulation and causing hydrocepha-
lus. In other cases, dural venous hypertension 
may result in decreased absorption of CSF 
  
with secondary intracranial hypertension and 
papilledema. This latter complication appears 
to be more common in association with high 
flow lesions draining into large dural venous 
sinuses and in the setting of concomitant dural 
sinus outflow obstruction.
Particular clinical presentations take place with 
DAVMs in specific locations. 12, 36, 39, 40 DAVMs 
in the region of the transverse or sigmoid sinus, 
or near the cavernous sinus, often drain into 
the associated venous sinuses and may cause 
a variety of clinical manifestations due to flow 
or local venous engorgement. A high flow in 
the region of the transverse-sigmoid sinus 
junction, for example, often results in pulsatile 
tinnutus, headache and bruit. This phenom-
enon does not lead to bleeding or cause other 
deficits unless there is associated retrograde 
leptomeningeal venous drainage. Lesions at the 
anterior cranial fossa or the tentorial incisura 
rarely drain into a patent dural venous sinus 
and are more frequently associated with lep-
tomeningeal venous drainage. They are more 
likely to cause serious clinical sequelae from 
venous hypertension and hemorrhage. It is 
important to mention that hemorrhage has not 
been reported in the absence of this feature; in 
all published cases with carefully documented 
diagnostic studies, hemorrhage from DAVMs 
is associated with rupture of arterialized venous 
structures. The prognosis of a first hemorrhage 
from DAVMs is ominous, and is associated with 
a greater than 30 percent mortality or serious 
disability. Hemorrhage from DAVMs in anti-
coagulated patients has uniformly been fatal. 
Classification
Location
Classification of DAVMs has evolved over time 
to be useful in guiding therapeutic intervention. 
Initial attempts were simplistic, emphasizing 
the anatomic location (e.g., transverse-sigmoid 
DAVM, cavernous DAVM, sagittal sinus 
DAVM, convexity DAVM, tentorial and pos-
terior fossa DAVM). These lacked meaningful 
information in regard to predicting the nature 
or outcome of the abnormality or treatment 
options. Subsequent systems incorporated 
information from diagnostic angiography. 5, 49, 50
Venous drainage
Perhaps one of the most well recognized 
classification schemes specific to DAVMs is 
that developed by Djindjian et al.49 This system 
categorizes a lesion into one of four types: 
type I DAVMs are characterized by normal 
anterograde drainage into a venous sinus or 
meningeal vein; type II lesions drain into a sinus, 
with reflux into adjacent sinuses or cortical veins; 
type III DAVMs drain directly into cortical veins 
with resultant retrograde flow into the cerebral 
venous compartment; type IV DAVMs have 
drainage directly into a venous pouch (venous 
lake or venous ectasia). They concluded from 
their study that type I DAVMs were benign, with 
each sequential type having more aggressive 
characteristics. Since the introduction of the 
Djindjian classification of DAVMs, other studies 
have been published in the literature attempting 
to correlate certain features of the DAVM with 
the likelihood of associated hemorrhage or other 
specific neurologic complications. 12, 39, 51, 52 
Table I: Classification of DAVMs
Type Djindjian Cognard Borden
I Normal antegrade flow into dural sinus Normal antegrade flow into dural sinus Drains directly into venous sinus or menin-
geal vein
II Drainage into venous sinus with reflux 
into adjacent sinus or cortical vein
a.  Retrograde flow into sinus Drains into dural sinuses or pachymenin-
geal veins with retrograde drainage into 
subarachnoid veins.b.  Retrograde filling of cortical veins only
c.  Retrograde drainage into sinus and cortical veins
d.  Drains into dural sinus or meningeal veins with 
retrograde drainage into subarachnoid veins.
III Drainage into cortical veins with  
retrograde flow
Direct drainage into cortical veins with retro-
grade flow
Drains into subarachnoid veins without 
dural sinus or meningeal involvement
IV Drainage into venous pouch (lake) Direct drainage into cortical veins with venous 
ectasia >5mm and 3x larger than diameter of 
draining vein
V Drainage to spinal perimedullary veins
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With the advent of more effective endovascular 
therapeutic techniques, a means of predicting 
lesion risk and management options emerged. 
Cognard et al. developed a classification system 
derived from a modified version of that pub-
lished by Djindjian et al.50 Cognard defined 
five types of DAVMs that are exclusively 
based on the pattern of venous outflow. As 
such, type I DAVMs were characterized by 
normal antegrade flow into the affected dural 
sinus. Type II lesions were associated with an 
abnormal direction of venous drainage within 
the affected dural sinus. These lesions could be 
further categorized into three subtypes: type 
IIa, lesions with retrograde flow exclusively into 
the sinus or sinuses; type IIb, lesions with ret-
rograde venous drainage into the cortical veins 
only; and type IIa+b, lesions with retrograde 
drainage into sinuses and cortical veins. Type 
III DAVMs drained directly into a cortical vein 
or veins without venous ectasia, whereas type 
IV DAVMs had drainage into cortical veins 
with the critical component of venous ectasia 
greater than 5 mm in diameter and three times 
larger than the diameter of the draining vein. 
A DAVM was considered to be type V when 
drainage was into spinal perimedullary veins. 
Correlation with their clinical data yielded 
the following conclusions: Type I DAVMs are 
considered benign, and treatment is usually 
not necessary, except possibly for palliation of 
symptoms; type IIa lesions are best treated with 
arterial embolization; while type IIb and IIa+b 
lesions usually require both transarterial and 
transvenous embolization for effective oblit-
eration. For those lesions of types III through 
V, transarterial and occasionally transvenous 
embolization aimed at complete occlusion of 
the fistula is necessary and usually will need to 
be combined with surgical techniques in eradi-
cating the threatening cortical venous drainage.
Meanwhile, Borden, et al., also proposed a clas-
sification system emphasizing venous anatomy. 5 
This system is appealing in its simplicity, 
with only 3 categories. Type I dural AVMs 
drain directly into dural venous sinuses or 
pachymeningeal veins. Type II malformations 
drain into dural sinuses or pachymeningeal 
veins but also have retrograde drainage into 
subarachnoid (leptomeningeal) veins. Type 
III malformations drain solely into subarach-
noid (leptomeningeal) veins and do not have 
dural sinus or meningeal venous drainage. 
The validity of both the Cognard and Borden 
classification systems were confirmed in 102 
intracranial DAVMs in 98 patients.52 (Table I)
Risk stratification
Regardless of lesion location or previous clini-
cal presentation or other symptomatology, the 
most important factor determining the propen-
sity of a lesion to an aggressive clinical course 
appears to be the presence of leptomeningeal 
venous drainage. Lesions that drain into a large 
patent venous sinus may have various clinical 
associations but do not bleed or cause focal 
neurological deficits unless associated with 
retrograde leptomeningeal venous drainage. 
Lesions without drainage into a patent dural 
venous sinus more frequently are associated 
with leptomeningeal venous drainage and 
more often are prone to more serious clinical 
sequelae, such as an intracerebral hemorrhage. 
As discussed, the risk of hemorrhage appears to 
be related directly to the presence of tortuous 
and aneurysmal leptomeningeal arterialized 
veins in association with DAVMs. 
Treatment
General principles of treatment
A DAVM may rarely be discovered on routine 
imaging studies on digital subtraction angi-
ography performed for other indications. 
Incidental lesions must be carefully assessed 
for features predisposing to aggressive clinical 
behavior. Complete angiographic evaluation 
is indicated in every case of suspected DAVM 
unless the patient is a poor candidate for thera-
peutic intervention or refuses invasive diag-
nostic studies. Lesions should be evaluated 
specifically for the presence of leptomeningeal 
venous drainage and for any variceal, aneu-
rysmal changes in the venous circulation or 
venous ectasia. In the absence of these features, 
the lesion should be followed expectantly. There 
is no evidence to justify prophylactic treatment 
of DAVMs that are not associated with lepto-
meningeal cortical venous drainage. Expectant 
follow-up of these lesions should include serial 
MR imaging for any evidence of development of 
leptomeningeal venous dilations. Angiographic 
re-examination of the lesion every few years 
should be considered, especially for DAVMs 
at the anterior cranial fossa or the tentorial 
incisura, which as discussed, very commonly 
harbor leptomeningeal venous drainage.
Definitive prophylactic treatment should be 
strongly considered for asymptomatic and 
incidentally discovered DAVMs with lepto-
meningeal venous drainage. The patient should 
be given the option of open surgical interven-
tion or such alternative radiosurgical or endo-
vascular options as may be appropriate for the 
specific lesion type and location. If treatment 
does not succeed at totally eliminating lepto-
meningeal venous drainage, either further 
definitive therapy or very close follow-up of 
the lesion is indicated. It is our belief that anti-
coagulation is contraindicated in the setting of 
DAVMs with leptomeningeal venous drainage.
Definitive intervention for DAVMs that in 
the past behaved aggressively warrants more 
serious thought. Nevertheless, the morbidity of 
a first hemorrhage with DAVMs is substantial, 
and many patients do not survive or do not 
recover to a condition suitable for therapeutic 
intervention. Furthermore, little is known 
about the risk either of subsequent hemorrhage 
or of the progression of neurological defi-
cits in this clinical setting. However, there are 
numerous documented cases of progression of 
focal neurological symptoms resulting in death 
or major disability unless the DAVM is obliter-
ated. It is our recommendation that lesions that 
have hemorrhaged or that cause focal neuro-
logical symptoms due to parenchymal venous 
hypotension be considered for definitive treat-
ment. Palliative therapy is not sufficient in 
this setting.
On the other hand, lesions that present with 
pain or pulsatile tinnitus are evaluated and 
treated in the same way as incidental lesions. 
Nonspecific measures aimed at the symptoms 
are usually sufficient. Palliative treatment of the 
DAVM may be considered for the control of 
symptomatology. Rarely is definitive treatment 
indicated solely for pain or pulsatile tinnitus. 
We do not believe that the risk of definitive 
treatment is justified in such DAVMs as they 
do not exhibit leptomeningeal venous drainage. 
Lesions associated with ophthalmoplegia are 
evaluated on a case-by-case basis. Frequently, 
painful ophthalmoplegia will resolve spontane-
ously, and many such lesions involute after angi-
ography. In other cases, ophthalmoplegia may 
be progressive or associated with retinopathy 
and visual loss. In such situations, treatment 
of the associated DAVM is justified. Palliative 
treatment may be sufficient to stabilize visual 
symptoms. Again, a radical cure of the DAVM 
should not be pursued at any risk, and is gener-
ally not warranted unless the symptoms are 
truly debilitating or the DAVM is associated 
with leptomeningeal venous drainage. 
The management of DAVMs associated with 
papilledema and increased intracranial pres-
sure has been discussed previously. Palliation 
or definitive cure of the DAVM frequently (but 
not always) results in reversal of papilledema 
and stabilization of visual symptoms. Again, 
in the absence of leptomeningeal venous 
drainage, the risk of radical lesion treatment 
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may not be justified, and may or may not 
result in subsequent control of intracranial 
hypertension. Cerebrospinal fluid diver-
sion via lumboperitoneal shunting or optic 
nerve sheath decompression may be com-
bined with transarterial embolization and 
or radiosurgery in the management of these 
entities. Transvenous occlusion is rarely 
possible in this setting, as it may further 
compromise intracranial venous outflow. 
Lumboperitoneal shunting or optic nerve 
sheath decompression may effectively treat 
Figure 1
This is a 46 y/o female who underwent embolization of a Right Temporo-Occipital DAVM. A) and B) Pre-embolization digital substraction angiography (DSA) images showing 
multiple arterial feeders (mostly from the occipital-meningeal system).  C) and D) Post-embolization DSA showing no supply from the meningeal system or occipital system after  
only one embolization session. 
A
C
B
D
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the secondary complications of papilledema 
while the DAVM is followed expectantly, 
treated palliatively, or with radiosurgery. 
Ventriculoperitoneal shunting may not be 
possible in view of small cerebral ventricles, 
and may be dangerous in the setting of arte-
rialized cortical or subependymal veins. 
In summary, clinical symptoms other than hem-
orrhage and progressive neurological deficits 
rarely warrant radical treatment of a DAVM, 
unless the lesion is particularly accessible 
Figure 2
This is a 51 y/o male receiving two different embolizations for right-side DAVM. A) and B) Pre-embo DSA showing multiple ECA feeders (mostly from the occipital-meningeal 
system) and cortical venous drainage (CVD). C) and D) DSA after 2 different embolizations showing persistent fistula filling and CVD. This patient subsequently needed a craniotomy 
for eradication of CVD. 
A
C
B
D
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or is associated with features predisposing to 
subsequent aggressive clinical behavior. Patient 
reassurance, symptomatic treatment, or lesion 
palliation is frequently sufficient. In DAVMs 
with features predisposing to an aggressive clin-
ical course, a more definitive treatment strategy 
should be adopted. It is obvious that the myriad 
of clinical manifestations of DAVMs and the 
wide spectrum of possible angiographic and 
pathophysiologic scenarios call for highly indi-
vidualized management strategies. Diagnostic 
investigation should be thorough so as to 
identify DAVMs with features predisposing 
to aggressive clinical behavior such as lepto-
meningeal cortical venous drainage or venous 
ecstasia. Treatment strategies should include a 
highly individualized choice of modalities from 
the available armamentarium of symptomatic 
treatment, lesion palliation, transarterial and 
/or transvenous endovascular therapy, open 
surgical invention, and radiosurgery. For the 
foreseeable future, the treatment of DAVMs 
should preferably be entrusted to multidisci-
plinary teams with expertise in the recogni-
tion and management of these lesions, and 
with experience in a variety of treatment 
options approaches.
Treatment strategy and location
Surgery
The goals of surgical treatment of DAVMs 
include 1) physical interruption or obliteration 
of arterialized leptomeningeal venous connec-
tions and 2) maximal coagulation or excision 
of the pathological dura . There is a continuous 
risk for significant blood loss. This is particularly 
true early in the procedure when incomplete 
exposure may be accompanied by significant 
bleeding. From the early steps of skin infiltra-
tion and incision, the operation should proceed 
in small steps, with hemostatic control before 
the subsequent step. This approach is indeed 
more speedy, efficient and safe than having 
to take time to control brisk bleeding from 
many sources. As a rule, no incision should be 
made unless one was prepared to control cata-
strophic bleeding from it. A thorough review 
of preoperative angiography and judicious 
use of preoperative embolization helps to limit 
this risk. Continuous communication with the 
anesthesia team is critical. 
Meticulous attention to hemostasis and micro-
surgical technique is imperative throughout 
the procedure.53 Following identification, 
resection of the abnormal dura is aided by the 
irrigating bipolar. Small permanent vascular 
clips in tandem, alternated with dural tran-
section may be useful. Temporary aneurysm 
clips are helpful in decision making prior to 
coagulation and sectioning of variceal veins, 
which may significantly impact adjacent corti-
cal venous circulation. It is sometimes possible 
to identify discrete arteriovenous connections 
whose occlusion significantly decreases sur-
rounding subarachnoid venous engorgement. 
Direct puncture of large varices with intra-
operative placement of obliteratingcoils has 
been used successfully.54 A combination of 
coils and glue after obtaining access by cra-
niectomy and direct sinus puncture has also 
been reported.55 Resection of the dural sinus 
can be accomplished without the risk of venous 
infarction if the resected segment is arterialized 
and collateral channels are well developed.56 
In some cases, surgical clipping of the drain-
ing vein close to the DAVM, with extensive 
dural coagulation rather than resection may 
be preferred.57 Recently, presigmoid skull base 
exposures have been employed, specifically for 
access to petrosal and sigmoid lesions.58 Image 
guided frameless navigation is useful for flap 
design and localization of DAVMs or associ-
ated cortical venous drainage. Intraoperative 
angiography helps to ensure complete resection 
in difficult cases. 
Endovascular techniques
Transarterial embolization has been widely 
used in the treatment of DAVMs.1, 59, 60 The 
use of flow-guided catheter technology and 
increased experience with particle and glue 
embolization as well as detachable coils have 
greatly improved the safety and efficacy of this 
method.61–63 However, transarterial emboliza-
tion rarely succeeds in totally eliminating and 
curing a DAVM, except in rare instances of lim-
ited fistulae with a small number of accessible 
feeders. More commonly, DAVMs involve a 
multitude of feeders, which often arise as small 
twigs from major cerebral arteries that are not 
amenable to embolization. While transarterial 
embolization may obliterate the filling of the 
lesion after one injection, the DAVM often 
continues to draw feeders from other sources, 
and will reappear on subsequent angiography, 
possibly in a more ominous configuration. 
DAVMs that are partially treated with transar-
terial embolization may later recur and progress 
to catastrophic hemorrhage.
What transarterial embolization can do is to 
palliate disabling symptoms even when it does 
not totally cure the DAVM. Symptom pallia-
tion may be accomplished by transarterial 
embolization of external carotid artery feeders 
to the DAVM, although such an intervention is 
not without risk and rarely succeeds in totally 
eliminating the DAVM. Arterial embolization 
may give a false sense of security that the lesion 
was “treated” while the DAVM may progress 
to acquire more aggressive features including 
leptomeningeal venous drainage (even in the 
absence of recurrent symptoms). DAVMs that 
are followed expectantly or treated palliatively 
should be monitored closely with serial diag-
nostic studies to watch for the development of 
leptomeningeal venous drainage, which may 
occur without change in clinical symptoms. 
Such lesions should continue to be followed 
as discussed above. Transarterial emboliza-
tion also plays an important role in decreasing 
flow through DAVMs prior to surgical inter-
vention, transvenous obliteration, or radio-
surgery .64–66 This adjunctive, preparatory 
use of transarterial embolization has greatly 
enhanced the safety and efficacy of other more 
definitive treatment measures. 
Noninvasive imaging methods, including MRI 
and MRA may be used for interval studies, 
although these modalities may miss subtle 
development of leptomeningeal venous drain-
age, which may be clinically catastrophic. 
Depending on the clinical situation and the 
particular lesion, serial MR studies may be 
performed on a yearly basis, with formal angi-
ography every few years or sooner if symptoms 
change, or if there is a suggestion of new lepto-
meningeal venous drainage on MRI .
Transvenous endovascular obliteration of 
DAVMs has recently been used with good 
results .67–69 This modality aims at the throm-
bosis of the venous side of the lesion, often 
including the obliteration of the adjacent 
dural venous sinus. Occlusion of the venous 
side of DAVMs is usually well tolerated if 
the pathologic dural sinus is arterialized and 
does not serve as a site of drainage of cere-
brovenous circulation. Instead, the pathologic 
dural segment is often associated with harmful 
retrograde leptomeningeal venous drainage, 
and these channels are secondarily obliterated 
with thrombosis of the venous side of DAVMs. 
This strategy has been used most successfully 
for the treatment of DAVMs with accessible 
venous drainage. Transvenous obliteration 
is particularly effective in the treatment of 
cavernous sinus DAVMs (access through the 
inferior petrosal sinus), although these lesions 
frequently do not require any therapeutic 
intervention because of their benign clinical 
symptomatology and tendency toward spon-
taneous regression. 
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Transvenous obliteration has also been used 
in cases of transverse-sigmoid sinus DAVMs, 
and may be substantially safer than open 
surgical approaches to these lesions. However, 
there may be no accessible transvenous route 
for many DAVMs, including tentorial inci-
sura DAVMs and anterior cranial fossa 
DAVMs, which frequently behave aggressively. 
Transvenous obliteration may occasionally 
be performed after open surgical exposure, 
through puncture of the dural venous sinus or 
the arterialized venous varix and the injection 
of coils or glue. 54 Rarely, transvenous occlusion 
may result in propagating venous thrombosis 
or altered hemodynamic patterns with para-
doxical clinical deterioration or hemorrhage. 
Occasionally, a DAVM will recur adjacent to 
endovascularly occluded venous sinus, and this 
could represent reconstitution of arteriovenous 
channels within the walls of the occluded sinus, 
or in the organized thrombus within the sinus 
channel. These cases are amenable to surgical 
excision of the segment of occluded sinus, and 
disconnection of associated arterialized lepto-
meningeal veins.
Radiosurgery
The goal of radiosurgical treatment is sclerosis 
and obliteration of arteriovenous connec-
tions within the pathological dura, resulting 
in secondary thrombosis of the DAVM. 
Advantages include non-invasive treatment 
and avoidance of risks associated with invasive 
procedures. Disadvantages include delayed 
response to treatment and risk of radiation 
injury to normal structures in the vicinity of 
the DAVM. When combined with transarterial 
embolization, 95% of patients demonstrated 
symptomatic improvement and 87% demon-
strated angiographic cure on angiography 
performed a median of 12 months following 
radiosurgery.70 There was an acceptable 
complication rate with this treatment strategy. 
Radiosurgery alone was effective when the 
DAVM was not amenable to embolization but 
the time course for symptomatic improvement 
was longer. 
DAVMs of the transverse-sigmoid sinuses 
treated with a similar strategy yielded a 96% 
symptom resolution or significant improve-
ment and a total or near-total obliteration 
at mean angiography 21 months following 
radiosurgery. 66 There were no intracerebral 
hemorrhages or radiation-related complica-
tions. While the ideal treatment parameters 
and ultimate role of radiosurgery continue to 
evolve, it has an established role in the multi-
modality treatment of DAVMs. 
The Thomas Jefferson Experience
Background
We have amassed the longest reported follow-
up of 39 patients who were initially treated by 
endovascular means. These patients were sub-
sequently evaluated throughout their treatment 
plan in order to discern whether multi-modality 
therapy would be necessary or not or whether 
strict endovascular therapy would suffice. We 
hereby report their outcomes and complica-
tions. Our follow-up involves patients who 
were electively referred to our institution who 
had a non-invasive study (such as an MRA) 
illustrating the DAVM as well as those who 
presented with an intracerebral hemorrhage. 
The sequence of events involved a diagnostic 
angiogram followed by endovascular emboliza-
tion as the primary means of treatment. 
Thirty-nine patients (22 males and 17 females) 
underwent endovascular treatment of dural 
AVMs at our primary institution from 2001–
2009. Ages ranged from 39–71 (mean age: 48). 
Seventy-nine percent of patients had cortical 
venous drainage.  
Methods
We studied the following outcome factors: 
1) the number of embolizations needed to 
obliterate the lesion, and 2) the percentage of 
patients requiring transvenous embolization, 
craniotomy, or radiosurgery for eradication of 
the lesion after endovascular management. 
We also inspected whether those patients who 
were initially found to have retrograde cortical 
venous drainage had subsequent eradication of 
this phenomenon after multi-modality therapy. 
Finally, we assessed post operative complica-
tions from either of the modalities.
Results
Outcomes toward Obliteration  
of Fistulous Component
The number of endovascular embolizations 
performed in order to decide on whether 
to proceed with surgery, radiosurgery or 
ascertain complete obliteration of the fistu-
las was 2.1. This was an average obtained 
by adding up the number of endovascular 
embolizations needed to obtain at least a 
95% reduction in fistula flow in all patients 
studied. We deemed the DAVM as “treated” 
when this result was obtained as per the 
observation of the angiographer. Seventy-
one percent (71%) (28/39) of patients had 
complete obliteration of the fistula; 21 of 
those by endovascular means and 7 via cra-
niotomy. Figure 1 illustrates eradication of the 
DAVM after one embolization session. 
Of the eleven patients who did not have com-
plete obliteration of the fistula, seven of those 
(64%) had at least 90% obliteration with only 
one feeding pedicle remaining. Three patients 
needed radiosurgery as a final approach for 
treatment. The average dose utilized for eradica-
tion of the DAVM was 22 Gy in single fraction.
Outcomes Toward Eradication of Retrograde Cortical 
Venous Drainage
We studied whether retrograde cortical venous 
drainage would be eradicated by various 
components of multi-modality therapy. 87% 
(26/30) of patients had full obliteration of their 
cortical venous drainage. Of these 26 patients, 
69% (18/26) had obliteration obtained by endo-
vascular means while the rest needed surgical 
venous ligation. Figure 2 illustrates treatment 
of a patient by multi-modality therapy to eradi-
cate both the cortical venous drainage phe-
nomenon as well as the fistulous component. 
It is interesting to note that in five of these 18 
patients who had CVD treated endovascularly, 
success was only obtained when a transvenous 
approach was performed. 
Complications
The following complications were noticed: 
epidural infection after craniotomy (1), post op 
intracranial hemorrhage not requiring surgery 
after embolization (1), and need for vein patch 
procedure after uncontrolled femoral bleeding 
(1). All above complications were diagnosed 
and treated expeditiously.  
Analysis
Endovascular treatment of DAVMs is a safe 
and effective way to treat these complex 
lesions. Additional modalities such as surgery 
and radiosurgery have become adjuvant in the 
treatment of these lesions. We strongly believe 
based on this data that endovascular emboliza-
tion should be the primary modality for treating 
DAVMs.
Prognosis and outcome 
An established DAVM has an unpredictable 
natural course, varying from spontaneous 
regression to more venous recruitment and 
hemorrhage, depending on the presence or 
absence of leptomeningeal venous drainage. 
The prognosis of a first hemorrhage from 
DAVMs is ominous, and has been shown to be 
associated with greater than 30% mortality or 
serious disability. The annual bleeding risk of a 
DAVM varies between 1.8 to 15% ,71 the risk of 
rebleed over the period of two weeks has been 
estimated to be around 35%.38 The acute or 
gradual progression from one grade to the next 
has been described.
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Any change in the bruit or symptoms of a 
DAVM should warrant reevaluation to rule out 
the development of alternative drainage paths 
such as leptomeningeal drainage pathways. 
Recently carotid duplex sonography has been 
reported as a tool for follow up of treated dural 
AVMs, with a correlation of the resistance 
index of the external carotid artery with the 
effectivness of treatment.72
Conclusion
Much has been learned in recent years about 
the pathoanatomy, pathophysiology, natural 
history and therapeutic options for DAVMs. 
A better understanding of these lesions has 
allowed more prompt and precise diagnosis, 
and a realistic assessment of features predispos-
ing to aggressive clinical course. Treatment 
is not only guided toward the palliation of 
clinical symptoms, but as importantly, toward 
prevention of future sequelae. The therapeutic 
armamentarium includes a number of options 
with varying risk and effectiveness for individual 
lesions. Transarterial embolization, transvenous 
embolization, surgical therapy or radiosurgery 
can be used alone or in various combinations as 
required for individual clinical scenarios.
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“Time is brain” is the credo among healthcare 
professionals for diagnosing and treating time-
sensitive neurovascular diseases, including arterio-
venous malformations (AVMs), brain aneurysms and, 
especially, stroke.  e blood-clot busting medication 
tissue plasminogen activator (tPA), for example, must 
be administered to a patient having a stroke within 
4.5 hours for best chance of functional recovery. 
Timely performance of neurosurgical procedures 
to remove AVMs and aneurysms are similarly 
urgent. Yet many community hospitals have limited 
experienced sta  and technology to diagnose and 
treat patients quickly and accurately. 
Now, to provide sophisticated care and expertise 
to patients at hospital emergency rooms in small 
community hospitals in distant areas of eastern 
Pennsylvania, south and central New Jersey, and 
Delaware, Je erson Hospital for Neuroscience 
(JHN) in Philadelphia is launching Je erson Expert 
Teleconsulting (JET), the region’s  rst university-based 
high-tech mobile robotic system for neuroscience. 
“JET places all of our resources – among them, dual-
trained neurosurgeons, advanced technology, and 
leading-edge clinical trials in which we partner with the 
National Institutes of Health – at the disposal of patients, 
their families and physicians in need of a second, expert 
opinion,” says Robert H. Rosenwasser, MD, FACS, 
Professor and Chair, Department of Neurological 
Surgery, JHN and Je erson Medical College of  omas 
Je erson University. “Its greatest value is for timely 
diagnosis and application of treatment for time-sensitive 
neurovascular diseases, especially stroke.” 
Enhancing level of care 
“We want to partner with hospitals in other 
communities to help advance stroke care throughout 
the region. As the leading provider of stroke care 
in the region, we have an obligation to do that,” 
adds Pamela Kolb, Vice President, Neuroscience 
Service, JHN.
Supported by  omas Je erson University, a 
leading academic center, JHN is the region’s only 
dedicated hospital for neuroscience and leading, 
most experienced and comprehensive center for 
diagnosis and treatment of stroke and cerebrovascular 
disease. JHN’s Acute Stroke Center is the largest such 
facility, with more board-certi ed neurocritical care 
physicians than most, in the greater Delaware Valley. 
It is also a Joint Commission-accredited primary 
stroke center. 
“Stroke is the third-leading cause of death in the 
United States but the leading cause of disability, by a 
factor of  ve over any other disease,” Dr. Rosenwasser 
notes. “Given its prevalence and time-sensitive nature, 
it is alarming how few people receive treatment in the 
appropriate amount of time. With JET, even hospitals 
in remote areas can provide patients with expert 
consultation and disposition of appropriate care from 
an experienced neurologist or neurological surgeon 
immediately in cases where every minute can make a 
critical di erence. It’s a very cost-e ective approach to 
providing 24/7 onsite coverage and expertise.”
How JET works 
Each participating hospital is supplied with a mobile 
robotic platform, manufactured by InTouch Health® 
of Santa Barbara, CA, that enables the JHN Network 
physician to be remotely present. JET’s panoramic 
visualization system and easy-to-use control interface 
a ord physicians, patients and hospital sta  a safe and 
e ective interactive experience.
InTouch’s remote presence devices are the  rst and 
only with FDA approval.  e robots allow direct 
connection to medical devices such as electronic 
stethoscopes, otoscopes and ultrasound to transmit 
medical data to the remote physician.
“Should a patient arrive in the ER of a hospital that’s 
located, say, three hours away from Je erson and 
either doesn’t have a neurologist or neurosurgeon 
available or has a neurologist who needs to consult 
with a neurosurgeon,” Dr. Rosenwasser, explains, “the 
attending physician contacts JHN.  e JHN Network 
specialist on call then uses a laptop to connect to 
the remote hospital via the robot, obtain a medical 
history by speaking directly with the patient and/or 
family members, examine the patient and determine 
what therapy is immediately needed, in real time, 
without delay. Finally, a decision is made either to 
admit the patient to the local hospital’s Critical Care 
Unit or transfer him or her to the Je erson Acute 
Stroke Center, by Je STAT, Je erson’s transport 
service, or the hospital’s own service.” 
“Patients may not need to be transferred – they can 
stay in their own community and be treated very 
successfully there, thanks to this program,” says Ms. 
Kolb. “And most patients want to stay close to home. 
JET enables them to receive sophisticated medical 
care without having to travel long distances.” 
“It also serves as an educational program,” adds Dr. 
Rosenwasser. “As a teaching center, JHN will use 
JET to share our clinical protocols with participating 
hospitals so that they can enhance stroke care within 
their communities. On the other hand, should the 
patient need an advanced neurosurgical procedure 
[See sidebar], we can arrange for prompt transfer.” 
JHN continues to set the standard worldwide 
for state-of-the-art care for time-sensitive 
neurovascular diseases. For more information 
about these and other treatments, visit 
www.JeffersonHospital.org/neuroscience.
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Pioneering Leading-Edge Treatments
Jefferson Hospital for Neuroscience staff have helped to 
develop and/or have introduced to the region leading-
edge treatments and technologies that reduce the need 
for open brain surgery for stroke, brain aneurysms and 
AVMs. Among them:
•  Intra-arterial thrombolysis with tPA – pharmacological 
blood clot-dissolving 
•  Mechanical thrombectomy devices – e.g., Merci 
Retrieval System® 
•  Wingspan stent – FDA-approved mesh tube to open 
blocked arteries in the brain after clot-dissolving drugs 
have failed
•  Coiling, gluing and stenting of brain aneurysms – 
reduces need for open brain surgery
Thomas Jefferson University and Hospitals www.JeffersonHospital.org/neuroscience
Redefining Healthcare 1-800-JEFF-NOW
JG 10-2013
10-01773
Announcing Je erson’s Teleconsulting (JET) Robotic System for Help with 
Diagnosis and Treatment of Time-Sensitive Neurovascular Diseases 
At Jefferson Hospital for 
Neuroscience, neurologist Michael 
M. Moussouttas, MD, and nurse 
Lauren Dougherty use the Jefferson 
Expert Teleconsulting (JET) system to 
consult with Robert H. Rosenwasser, 
MD, FACS, Chair, Department of 
Neurological Surgery (pictured on 
monitor), who is at another location.
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